Cited by 155Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Is Alzheimer's disease an apolipoprotein E amyloidosis?

Open access
Wisniewski, T., Lalowski, M., Golabek, A., Frangione, B., Vogel, T.·1995·The Lancet

Abstract

The presence of the apolipoprotein E4 allele has been identified as a major risk factor for late-onset Alzheimer's disease. Apolipoprotein E has also been found immunohistochemically in Alzheimer's disease lesions. We biochemically isolated amyloid beta from senile plaques and found that a carboxyl-terminal fragment (residues 216-299) of apolipoprotein E co-purified. In vitro this fragment from recombinant apolipoprotein E could form amyloid-like fibrils, which were Congo-red positive. Thus senile plaques may contain both amyloid beta and apolipoprotein E amyloid fibrils.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(95)90701-7

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 9 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Wisniewski, T., Lalowski, M., Golabek, A., Frangione, B., & Vogel, T.
Affiliations
NYU Langone Health (US)
Venue
The Lancet
Publisher
Elsevier BV
Published
1995-04
Volume
345
Issue
8955
Pages
956-958
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2012293927
Cited by
155
References
9
Citations by year
2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 8 · 2013: 2 · 2012: 7
FWCI
10.38
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r35ag010953-07)
  • National Institute on Aging (R01AG008721, AG-08721, AG10953, AG05891)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, apolipoprotein E, APOE ε4, amyloid-beta, amyloid plaques, amyloid fibrils, carboxyl-terminal fragment, Congo red, immunohistochemistry
MeSH terms
Alzheimer Disease, Amyloidosis, Apolipoproteins E, Brain Chemistry, Humans, Immunohistochemistry, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review